Search

Author/Creator Traynor, Anne M

1. A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α, 24(S)Dihydroxyvitamin D2) in patients with advanced cancer. (December 2015)

Authors:
Wisinski, Kari B; Ledesma, Wendy M; Kolesar, Jill; Wilding, George; Liu, Glenn; Douglas, Jeffrey; Traynor, Anne M; Albertini, Mark; Mulkerin, Daniel; Bailey, Howard H
Journal:
Journal of oncology pharmacy practice
Issue:
Volume 21:Number 6(2015)
Page Start:
416
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. Issue 12 (December 2017)

Authors:
Wakelee, Heather A; Dahlberg, Suzanne E; Keller, Steven M; Tester, William J; Gandara, David R; Graziano, Stephen L; Adjei, Alex A; Leighl, Natasha B; Aisner, Seena C; Rothman, Jan M; Patel, Jyoti D; Sborov, Mark D; McDermott, Sean R; Perez-Soler, Roman; Traynor, Anne M; Butts, Charles; Evans, Tr...
Journal:
Lancet oncology
Issue:
Volume 18:Issue 12(2017:Dec.)
Page Start:
1610
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Assessment of adherence and relative dose intensity with oral chemotherapy in oncology clinical trials at an academic medical center. (July 2018)

Authors:
Engle, Jeff A; Traynor, Anne M; Campbell, Toby C; Wisinski, Kari B; LoConte, Noelle; Liu, Glenn; Wilding, George; Kolesar, Jill M
Journal:
Journal of oncology pharmacy practice
Issue:
Volume 24:Number 5(2018)
Page Start:
348
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗